ImmuCell (ICCC) VP Brockmann granted 5,000 incentive stock options

Rhea-AI Filing Summary

ImmuCell Corp. vice president Bobbi Jo Brockmann received a grant of 5,000 incentive stock options for company common stock. The options carry an exercise price of $5.49 per share and relate to 5,000 underlying common shares. They are reported as directly owned and expire on April 16, 2030.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brockmann Bobbi Jo

Role VP of Sales and Marketing

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Options (Right to buy)	5,000	$0.00	--

Holdings After Transaction: Incentive Stock Options (Right to buy) — 5,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 5,000 options Exercise price: $5.49 per share Underlying shares: 5,000 shares +2 more

5 metrics

Options granted 5,000 options Incentive stock options awarded to VP Bobbi Jo Brockmann

Exercise price $5.49 per share Price to buy ImmuCell common stock under options

Underlying shares 5,000 shares Common stock underlying the incentive stock options

Expiration date April 16, 2030 Date on which unexercised options lapse

Total options after grant 5,000 options Total derivative holdings reported following this transaction

Key Terms

Incentive Stock Options, Form 4, exercise price, underlying security, +1 more

5 terms

Incentive Stock Options financial

"Incentive Stock Options (Right to buy)"

Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

exercise price financial

"conversion_or_exercise_price": "5.4900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title": "Common Stock""

expiration date financial

"expiration_date": "2030-04-16T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brockmann Bobbi Jo

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP of Sales and Marketing

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Options (Right to buy)	$5.49	04/16/2025		A		5,000		04/16/2028	04/16/2030	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

Remarks:

The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ImmuCell (ICCC) executive Bobbi Jo Brockmann report on this Form 4?

Bobbi Jo Brockmann reported receiving 5,000 incentive stock options for ImmuCell common stock. These are compensation-related options, not an open-market share purchase, and give her the right to buy 5,000 shares at a preset exercise price.

How many ImmuCell (ICCC) stock options were granted to Bobbi Jo Brockmann?

She was granted 5,000 incentive stock options. Each option represents the right to acquire one share of ImmuCell common stock, so the award covers 5,000 underlying shares if the options are eventually exercised.

What is the exercise price of Bobbi Jo Brockmann’s ImmuCell (ICCC) stock options?

The options have an exercise price of $5.49 per share. This means she can buy ImmuCell common stock at $5.49 for each option exercised, regardless of the market price at exercise time.

When do Bobbi Jo Brockmann’s ImmuCell (ICCC) options expire?

The incentive stock options expire on April 16, 2030. After that expiration date, any unexercised options will lapse and no longer give her the right to purchase ImmuCell common shares.

Is Bobbi Jo Brockmann’s ImmuCell (ICCC) Form 4 a stock purchase or a grant?

The Form 4 reports a grant of options, not a stock purchase. She received 5,000 incentive stock options as an award, giving her a future right to buy shares at $5.49, rather than buying shares in the market now.